In the first large-scale analysis of cancer gene fusions, researchers at the Wellcome Sanger Institute and their collaborators used CRISPR to uncover which gene fusions are critical for the growth of cancer cells. The team also identified a new gene fusion that presents a novel drug target for multiple cancers, including brain and ovarian cancers. The results give more certainty for the use of specific gene fusions to diagnose and guide the treatment of patients.
Source: EurekaAlert, https://www.eurekalert.org